Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Oncogene. 2022 Oct 12;41(46):5020–5031. doi: 10.1038/s41388-022-02491-8

Fig. 3. Both PARPi-resistant PEO1 cell lines show intact HR repair.

Fig. 3.

(a) Cells were treated with olaparib (5 μM) treatment for 48 hours. Immunofluorescence staining of RAD51 foci (green) was conducted for HR repair activity. Representative images were taken at 63x magnification (upper). Cells with > 5 RAD51 foci were counted as RAD51-positive (RAD51+) cells. The percentage of RAD51+ cells is plotted (bottom). (b) Immunoblotting of RAD51 in cells transfected with or without siRNAs against RAD51 (siRAD51, upper). DRGFP reporter assay was performed to measure the activity of HR repair as detailed in Materials and Methods (middle). The GFP-positive (GFP+) cells indicating HR-proficient cells were analyzed by flow cytometry (bottom). (c) Cell growth assays (XTT) were performed on cells transiently transfected with control siRNA (siControl) or RAD51-specific siRNAs (siRAD51) for 48 hours and treated with olaparib at indicated doses for a further 48 hours. *, p < 0.05; **, p < 0.01; ***, p < 0.001.